The stock of AC Immune SA (ACIU) has gone up by 18.63% for the week, with a 6.45% rise in the past month and a -10.81% drop in the past quarter. The volatility ratio for the week is 6.50%, and the volatility levels for the past 30 days are 5.77% for ACIU. The simple moving average for the past 20 days is 15.01% for ACIU’s stock, with a 3.67% simple moving average for the past 200 days.
Is It Worth Investing in AC Immune SA (NASDAQ: ACIU) Right Now?
ACIU has 36-month beta value of 1.24. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ACIU is 61.76M, and currently, short sellers hold a 1.22% ratio of that float. The average trading volume of ACIU on September 19, 2024 was 165.79K shares.
ACIU) stock’s latest price update
AC Immune SA (NASDAQ: ACIU)’s stock price has soared by 4.91 in relation to previous closing price of 3.46. Nevertheless, the company has seen a gain of 18.63% in its stock price over the last five trading days. zacks.com reported 2024-08-06 that AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.42. This compares to loss of $0.22 per share a year ago.
Analysts’ Opinion of ACIU
Many brokerage firms have already submitted their reports for ACIU stocks, with BTIG Research repeating the rating for ACIU by listing it as a “Buy.” The predicted price for ACIU in the upcoming period, according to BTIG Research is $8 based on the research report published on May 31, 2024 of the current year 2024.
ACIU Trading at 5.89% from the 50-Day Moving Average
After a stumble in the market that brought ACIU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.38% of loss for the given period.
Volatility was left at 5.77%, however, over the last 30 days, the volatility rate increased by 6.50%, as shares surge +7.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.01% upper at present.
During the last 5 trading sessions, ACIU rose by +18.63%, which changed the moving average for the period of 200-days by +9.67% in comparison to the 20-day moving average, which settled at $3.17. In addition, AC Immune SA saw -27.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACIU starting from ANDREA M. A PFEIFER, who proposed sale 20,000 shares at the price of $3.46 back on Sep 18 ’24. After this action, ANDREA M. A PFEIFER now owns shares of AC Immune SA, valued at $69,200 using the latest closing price.
Stock Fundamentals for ACIU
Current profitability levels for the company are sitting at:
- -3.88 for the present operating margin
- -2.83 for the gross margin
The net margin for AC Immune SA stands at -3.91. The total capital return value is set at -0.44. Equity return is now at value -46.46, with -31.02 for asset returns.
Based on AC Immune SA (ACIU), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 13.8. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -492.1.
Currently, EBITDA for the company is -50.37 million with net debt to EBITDA at 0.84. When we switch over and look at the enterprise to sales, we see a ratio of 16.74. The receivables turnover for the company is 9.96for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
To put it simply, AC Immune SA (ACIU) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
